UBS analyst Kevin Caliendo weighed in on Johnson & Johnson (NYSE: JNJ) after the company confirmed plans to split into ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE